CARB-X News

• 04.30.2026  |  CARB-X releases 2025 Annual Report highlighting portfolio momentum and new funding

  CARB-X today published its 2025 Annual Report documenting continued progress across the portfolio, the addition of new funding partnerships with G7 nations, and growing contributions to strengthen the antimicrobial resistance (AMR) ecosystem.

  Full Story

• 04.28.2026  |  CARB-X awards funding to AdJane to advance its nOMV platform-derived vaccine for the prevention of gonorrhea

  CARB-X is awarding US$2.6 million to AdJane to advance the development of a vaccine candidate to prevent infections caused by Neisseria gonorrhoeae (N. gonorrhoeae). AdJane is a clinical-stage vaccine platform company based in the Netherlands that utilizes its native Outer Membrane Vesicle (nOMV) platform to address antimicrobial resistance, pandemic preparedness, and global health challenges. 

  Full Story

• 04.07.2026  |  The European Commission invests in CARB-X and GARDP to ramp up global response to antimicrobial resistance

  The European Commission’s DG Health Emergency Preparedness and Response Authority (DG HERA) announced today at the One Health Summit in Lyon a new €30 million EU4Health investment managed by KfW, Germany’s Development Bank, to Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Global Antibiotic Research & Development Partnership (GARDP) to strengthen the global response to antimicrobial resistance (AMR).

  Full Story

• 03.04.2026  |  CARB-X provides funding to Myers Research Group to develop antibiotic targeting drug-resistant pathogens

  CARB-X is awarding US$1.2 million to the Andrew G. Myers Research Group at the Harvard University Department of Chemistry and Chemical Biology to develop enhanced antibiotics that target multi-drug-resistant Gram-negative bacterial pathogens, including Escherichia coli and Klebsiella pneumoniae, to treat urinary tract infections, pneumonia, and bloodstream infections.

  Full Story

• 02.26.2026  |  CARB-X launches 2026 funding round to address global burden of AMR

  CARB-X announced today a funding solicitation targeting the global burden of antimicrobial resistance (AMR).

  Full Story

• 02.05.2026  |  CARB-X to support development of typhoid fever diagnostic from Chembio

  CARB-X is awarding US$1.8million to Chembio Diagnostic Systems, Inc. to develop a rapid point-of-care test for the detection of Immunoglobulin A (IgA) antibodies to diagnose acute infection of Salmonella enterica serovar Typhi.

  Full Story

• 01.28.2026  |  Wellcome renews AMR innovation partnership with CARB-X with US$60M award

  CARB-X announced today its renewed partnership with Wellcome, a global charitable foundation which co-founded CARB-X in 2016. Between 2026 and 2028, Wellcome will provide CARB-X with new funding of up to US$60 million to support early-stage research and development of innovative antibacterial products to protect lives from bacterial infections globally.

  Full Story

• 01.08.2026  |  CARB-X announces new chemistry-focused theme ahead of 2026 funding call

  CARB-X is seeking applications for novel chemistry plans against known antimicrobial resistance (AMR) targets. The aim is to unlock innovative starting points for therapeutics to address dangerous, drug-resistant bacterial infections.

  Full Story